Entresto (sacubitril/valsartan) Cost, Side Effects, Dose, Approval, And Mechanism For Treating Heart Failure | Sasha Gould, PharmD | RxEconsult
Menus

All Health Articles

Entresto (sacubitril/valsartan) Cost, Side Effects, Dosing, And Mechanism For Treating Heart Failure Category: Heart Disease by - July 29, 2015 | Views: 73986 | Likes: 2 | Comment: 0  

How effective is Entresto?

The PARADIGM-HF trial compared the efficacy of Entresto 200 mg (97/103 mg) twice daily versus enalapril 10 mg twice daily in 8,442 patients with NYHA Class II-IV heart failure and systolic dysfunction. Patients were already taking the maximum tolerated dose of a beta blocker and an angiotensin converting enzyme inhibitor (ACEi) or ARB. The median follow-up duration was 27 months and patients were treated for up to 4.3 years. At the conclusion of the study, 21.8% of patients in the Entresto group had a cardiovascular (CV) event or were hospitalized compared to 26.5% of patients who received enalapril. The Entresto treatment group also had a lower rate of death from cardiovascular causes when compared to the enalapril treatment group (13.3% versus 16.5%). Entresto was superior to enalapril in reducing the risk of cardiovascular death, hospitalizations due to heart failure, and all-cause mortality. 

Interesting Facts about Entresto

  • Entresto is the first drug in a new class of medications known as angiotensin-receptor neprilysin inhibitors (ARNIs)

  • Sacubitril is a prodrug.

  • The PARADIGM-HF clinical trial was ended early because Entresto was very effective.

  • Entresto was shown to be better than enalapril, an ACEi, which is a gold standard treatment for patients with heart failure and low ejection fraction.

Next: Side Effects, Dosage, Drug Interactions

 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2021 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap